Aurinia SVP has 11,552 shares withheld for taxes

Aurinia Pharmaceuticals senior vice president and chief medical officer Greg Keenan reported a routine share withholding tied to equity compensation.

Accepted by SEC EDGAR 02/03/2026 - 04:49 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Aurinia Pharmaceuticals senior vice president and chief medical officer Greg Keenan reported a routine share withholding tied to equity compensation. On 02/02/2026, 11,552 shares of common stock were withheld at $14.53 per share to satisfy tax obligations when restricted stock units vested.

After this tax-related withholding, Keenan beneficially owns 121,932 shares of Aurinia common stock, held directly. The filing reflects an administrative adjustment rather than an open-market purchase or sale, and confirms his ongoing equity stake in the company.

Insider Trade Summary

Exercise Price or Tax Liability: 11,552 shares

Exercise Price or Tax Liability 1 txn

Insider Keenan Greg

Role SVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Exercise Price or Tax Liability	Common Stock	11,552	$14.53	$168K

Holdings After Transaction: Common Stock — 121,932 shares (Direct)

Footnotes (1)

1. F1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Aurinia (AUPH) SVP Greg Keenan report?

Greg Keenan reported a tax-related share withholding. On 02/02/2026, 11,552 Aurinia common shares were withheld at $14.53 per share to cover tax obligations arising from the vesting of restricted stock units, as disclosed in his Form 4 filing.

How many Aurinia (AUPH) shares does Greg Keenan own after this Form 4?

After the reported transaction, Greg Keenan beneficially owns 121,932 Aurinia common shares directly. This figure reflects his holdings following the 11,552 shares withheld to satisfy tax obligations associated with the vesting of restricted stock units on 02/02/2026.

Did Aurinia (AUPH) SVP Greg Keenan sell shares on the open market?

The filing shows no open-market sale. Instead, 11,552 Aurinia common shares were withheld at $14.53 per share to satisfy tax withholding obligations triggered by the vesting of restricted stock units, a common administrative mechanism for equity compensation.

What does transaction code "F" mean in Greg Keenan’s Aurinia (AUPH) Form 4?

Transaction code "F" indicates shares were used to pay taxes on equity awards. In this case, 11,552 Aurinia common shares were withheld to satisfy tax withholding obligations when Greg Keenan’s restricted stock units vested, rather than representing a discretionary sale.

What position does Greg Keenan hold at Aurinia (AUPH) in this Form 4?

Greg Keenan is identified as an officer of Aurinia, serving as senior vice president and chief medical officer. The Form 4 confirms his role and reports a tax-withholding transaction related to the vesting of restricted stock units tied to his compensation.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keenan Greg

(Last) (First) (Middle)

#140, 14315 - 118 AVENUE

(Street)

EDMONTON A0 T5L 4S6

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Aurinia Pharmaceuticals Inc. [ AUPH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/02/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/02/2026		F		11,552(1)	D	$14.53	121,932	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares withheld to satisfy tax withholding obligations upon the vesting of restricted stock units.

Remarks:

	/s/ Greg Keenan, M.D.	02/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.